{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009216","form_type":"8-K","ticker":"NEPH","cik":"0001196298","company_name":"NEPHROS INC","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.586213+00:00","generated_at":"2026-06-05T01:09:47.654643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nephros FY2023 revenue up 43% to $14.2M; net loss narrows to $1.6M from $4.3M","bullets":["Full-year net revenue from continuing ops $14.2M, up 43% YoY; Q4 revenue $3.3M, up 27%.","Net loss from continuing ops improved 63% to ($1.6M) for FY2023 vs ($4.3M) in 2022.","Adjusted EBITDA loss from continuing ops narrowed to ($0.1M) for FY2023, an improvement of 97%.","Cash and cash equivalents $4.3M at Dec 31, 2023; company remains debt-free.","CEO cites regulatory tailwinds from new water safety standards like ASHRAE 514 driving growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009216","json":"https://secwatch.observer/filing/0001493152-24-009216.json","markdown":"https://secwatch.observer/filing/0001493152-24-009216.md","text":"https://secwatch.observer/filing/0001493152-24-009216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1196298/000149315224009216/0001493152-24-009216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1196298/000149315224009216/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:09:47.654643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a77d5f34df99958519843a9acb6ebaa3ae52f242","claim":"NEPHROS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue Net revenue from continuing operations was $14.2 million, net income Net loss from continuing operations was ($1.6 million).","evidence_excerpt":"Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1196298/000149315224009216/0001493152-24-009216-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"Net revenue from continuing operations was $14.2 million"},{"label":"Net income","value":"Net loss from continuing operations was ($1.6 million)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}